Related references
Note: Only part of the references are listed.My road to Damascus: how I converted to the prohormone theory and the proprotein convertases
Michel Chretien
BIOCHEMISTRY AND CELL BIOLOGY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
Oystein L. Holla et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
Janice Mayne et al.
CLINICAL CHEMISTRY (2011)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
Effects of the Prosegment and pH on the Activity of PCSK9 EVIDENCE FOR ADDITIONAL PROCESSING EVENTS
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels The Coronary Artery Risk Development in Young Adults Study
Chiang-Ching Huang et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
Steve E. Humphries et al.
CLINICAL CHEMISTRY (2009)
The Molecular Basis of Familial Hypercholesterolemia in Lebanon: Spectrum of LDLR Mutations and Role of PCSK9 as a Modifier Gene
Marianne Abifadel et al.
HUMAN MUTATION (2009)
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
Marianne Abifadel et al.
HUMAN MUTATION (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Moonlighting proteins-an update
Constance J. Jeffery
MOLECULAR BIOSYSTEMS (2009)
Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
Yasuko Miyake et al.
ATHEROSCLEROSIS (2008)
Proprotein convertases as therapeutic targets
Michel Chretien et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Timothy S. Fisher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The proprotein convertases are potential targets in the treatment of dyslipidemia
Nabil G. Seidah et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Yue-Wei Qian et al.
JOURNAL OF LIPID RESEARCH (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
Tommaso Fasano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women
David Evans et al.
BMC MEDICAL GENETICS (2006)
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
P Yue et al.
HUMAN MUTATION (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review
MA Austin et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
